ĐÁNH GIÁ HIỆU QUẢ ĐIỀU TRỊ PHÁC ĐỒ ZIDOVUDINE + LAMIVUDINE + LOPINAVIR/RITONAVIR Ở BỆNH NHÂN HIV/AIDS THẤT BẠI VI RÚT HỌC VỚI PHÁC ĐỒ BẬC 1 TẠI HẢI PHÒNG

Abstract

Objectives: To evaluating the efficiency and safety of Zidovudine + Lamivudine + Lopinavir/ritonavir regimen in HIV/AIDS patients with first - line treatment failure.

Subjects and methods: Retrospective and prospective cohort studies on 65 patients with virological failure with first-line regimens (TDF + 3TC + NVP or TDF + 3TC + EFV), switched to ZDV + 3TC + LPV/r at Viet - Tiep Hospital from June 2012 to June 2019.

Results: Virologic failure (HIV - RNA > 1000 copies/mL): has not been well etablished at 6,12,24 months (M) after the end therapy. Mean CD4 cell count increased significantly in M24: 316 ± 184 cell/mm3, compared with T0 of 131 ± 118 cell/mm3. The most common side effect of AZT + 3TC + LPV/rismild to moderate anemia (55.3%), diarrhea (29.1%). The type of dyslipidemia occurs at all times and the proportion of patients with dyslipidemia after treatment were higher than startingphase.

Conclusions: AZT + 3TC + LPV/r on treatment had been shown to be clinically, virologically and immunologically effective in patients with first-line treatment failure.